Find a Pharmacy
Vertice Login
Info banner
A significant part of the Healthesystems vision is to create a more integrated experience for our customers

What's Happening

Stay up to date on conferences, social posts, and what’s new with Healthesystems

Events

Let’s connect at one of our upcoming conferences or speaking engagements
April 20 - Apr 22, 2026

IAIABC Forum

Healthesystems is attending the IAIABC Forum, a conference discussing policy and administrative issues in workers' comp.

Greenville. SC
April 20 - Apr 22, 2026

IRSG

Healthesystems is attending the IRSG Conference, which is designed for leaders in the insurance, medical, and rehabilitation fields.

Nashville, TN
View all Events

MedMonitor

An up-to-date timeline of FDA approvals that could impact workers' comp
View All MedMonitor Information

Flovent HFA (fluticasone propionate) metered inhalation aerosol

Approval Date: Mar 2026

Note: First-Time Generic

An inhaled corticosteroid indicated for the maintenance treatment of asthma as a prophylactic therapy, and for the treatment of asthma in patients requiring oral corticosteroids

hello world!

Briviact (brivaracetam) oral solution

Approval Date: Feb 2026

Note: First-Time Generic

Indicated for the treatment of partial-onset seizures

hello world!

Briviact (brivaracetam) injection

Approval Date: Feb 2026

Note: First-Time Generic

Indicated for the treatment of partial-onset seizures

hello world!

Nucynta (tapentadol hydrochloride) oral solution

Approval Date: Jan 2026

Note: First-Time Generic

An opioid analgesic indicated for the relief of moderate to severe pain

hello world!

Nucynta (tapentadol hydrochloride) tablets

Approval Date: Jan 2026

Note: First-Time Generic

An opioid analgesic indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate in patients weighing at least 40 kg

hello world!

Odefsey (Emtricitabine, rilpivirine and tenofovir alafenamide) tablets

Approval Date: Jan 2026

Note: First-Time Generic

Indicated as a complete regimen for the treatment of HIV-1 infection in patients weighing at least 35 kg as initial therapy in those with no antiretroviral treatment history with HIV-1 RNA less than or equal to 100,000 copies per mL; or to replace a stable antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) for at least six months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Odefsey

hello world!

Avtozma® (tocilizumab-anoh) injection

Approval Date: Jan 2026

Note: New Drug, Biosimilar

Indicated for the treatment of rheumatoid arthritis, giant cell arthritis, cytokine release syndrome, and COVID-19

hello world!

Exdensur (depemokimab-ulaa) injection

Approval Date: Dec 2025

Note: New Drug, Biologic

Indicated for add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype (a type of inflammation characterized by high levels of white blood cells) in patients

hello world!

Wegovy® (semaglutide) oral tablets

Approval Date: Dec 2025

Note: New Formulation

Indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in obese adults and overweight adults with at least one weight-related comorbidity. This approval is for a new oral tablet formulation of Wegovy, making it the first orally available GLP-1 medication for obesity.

hello world!

Jascayd® (nerandomilast) tablets

Approval Date: Dec 2025

Note: New drug

Indicated for the treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis

hello world!

Boncresa (denosumab-mobz) injection

Approval Date: Dec 2025

Note: Biosimilar

A biosimilar to Prolia® (denosumab), this drug is a RANKL inhibitor indicated for the treatment of osteoporosis in postmenopausal women with high risk of fracture, to increase bone mass in men with osteoporosis at a high risk for fracture, for the treatment of glucocorticoid-induced osteoporosis in men and women with high risk of fracture, and more

hello world!

Janumet® (sitagliptin and metformin hydrochloride) tablets

Approval Date: Dec 2025

Note: First-Time Generic

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, this approval is for a first-time generic

hello world!

Diastat® AcuDial (diazepam) rectal gel delivery system

Approval Date: Nov 2025

Note: First-Time Generic

Indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern. This approval is for a first-time generic

hello world!

Javadin (clonidine hydrochloride) oral solution

Approval Date: Oct 2025

Note: New Formulation

Indicated for the treatment of hypertension to lower blood pressure, a new oral solution formulation of this drug is now available

hello world!

Bondlido® (lidocaine topical system)

Approval Date: Sep 2025

Note: New Drug

A lidocaine and amide local anesthetic patch indicated for the relief of pain associated with post-herpetic neuralgia (shingles pain)

hello world!
1 2 3 12

Social Hub

Check out our latest posts and activity
View All Social Media
    lockmap-markermagnifiercrossmenucross-circle